Therapeutic approaches in management of drug-induced hepatotoxicity

Journal of Biological Sciences

Volumn 10, Issue 5, 2010, Pages 386-395

  Ansari, J A ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Clinical pattern of hepatotoxicity; Drug induced hepatotoxicity; Risk factors; Treatment approaches

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMIODARONE; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARNITINE; CHLORPROMAZINE; CIPROFLOXACIN; COLESTYRAMINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; DICLOFENAC; ENALAPRIL; ERYTHROMYCIN; ETHAMBUTOL; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; METHOTREXATE; METHYLDOPA; PARACETAMOL; PERHEXILINE; PYRAZINAMIDE; RIFAMPICIN; TIENILIC ACID; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CHOLESTATIC HEPATITIS; CONSULTATION; CYTOLYTIC HEPATITIS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG TOXICITY; DRUG WITHDRAWAL; EOSINOPHILIA; FEVER; HEPATITIS; HEPATOMEGALY; HUMAN; INFECTIOUS HEPATITIS; JAUNDICE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; PRURITUS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; TUBERCULOSIS;

EID: 77954768662     PISSN: 17273048     EISSN: 18125719     Source Type: Journal    
DOI: 10.3923/jbs.2010.386.395     Document Type: Article

References (61)

1. Andrade, R. J., M.I. Lucena, M.C. Fernandez, G. Pelaez and K. Pachkoria, 2005a. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology, 129: 512-521.
2. Andrade, R. J., F. J. Salmeron and I.M. Lucena, 2005b. Drug Hepatotoxicity. In: The Clinicians Guide to Liver Disease, Reddy, K.R. and T. Faust (Eds.). Slack Incorporated, New Jersey, USA.
3. Bass, N.M., 2003. Drug-Induced Liver Disease. In: Current Diagnosis and Treatment in Gastroenterology, Friedman, S., K. Mcquaid and J. Grendell (Eds.). 2nd Edn., McGraw-Hill Professional, New York, pp: 664-679.
4. Bateman, J., R.D. Chapman and D. Simpson, 1998. Possible toxicity of herbal medicines. Scott-Med. J., 43: 7-15.
5. Batt, A.M. and L. Ferrari, 1995. Manifestations of chemically induced liver damage. Clin. Chem., 41: 1882-1887.
6. Benowitz, N.L., M. J. Peng and P. Jacob, 2003. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin. Pharmacol. Ther., 74: 468-474.
7. Beyeler, C, J. Reichen and S.R. Thomann, 1997. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: A longitudinal study. Br. J. Rheumatol., 36: 338-344.
8. Brok, J., N. Buckley and C. Gluud, 2006. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst. Rev., 10.1002/14651858.CD003328
9. Burkhart, K.K., N. Janco, K.W. Kulig and B.H. Rumack, 1995. Cimetidine as adjunctive treatment for acetaminophen overdose. Hum. Exp. Toxicol., 14: 299-304.
10. CDC Update, 2003. Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States. MMWR, 52: 735-739.
11. CHMP, 2008. Committee for Medicinal Products for Human Use, Non-Clinical Guideline on Drug-Induced Hepatotoxicity. European Medicines Agency, London, pp: 2-16.
12. Chalasani, N., 2005. Statins and hepatotoxicity: Focus on patients with fatty liver. Hepatology, 41: 690-695.
13. Chalasani, N., H. Aljadhey, J. Kesterson, M.D. Murray and S.D. Hall, 2004. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 126: 1287-1292.
14. Chang, C.C., M. Petrelh, J.F. Tomashefski and A.J. Mccullough, 1999. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: A case report and review of the literature. Arch. Pathol. Lab. Med., 123: 251-256.
15. Deleve, L.D. and N. Kaplowitz, 2000. Prevention and Therapy of Drug-Induced Hepatic Injury. In: Therapy of Digestive Disorders: A Companion to Sleisenger and Fordtran Gastrointestinal and Liver Disease, Wolfe, M. (Ed.). WB Saunders, Philadelphia, pp: 334-348.
16. Desmet, V.J., P. van Eyken and T. Roskams, 1998. Histopathology of vanishing bile duct diseases. Adv. Clin. Pathol, 2: 87-99.
17. Edmondson, H.A., B. Henderson and B. Benton, 1976. Liver-cell adenomas associated with use of oral contraceptives. N. Engl. J. Med., 294: 470-472.
18. Egger, T., H. Dormann, G. Ahne, A. Pahl and U. Runge et al, 2005. Cytochrome p450 polymorphisms in geriatric patients: Impact on adverse drug reactions a pilot study. Drugs Aging, 22: 265-272.
19. Gordon, D.W., G. Rosenthal, J. Hart, R. Sirota and A.L. Baker, 1995. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA, 273: 489-490.
20. Green, R, R Grierson, D.S. Sitar and M. Tenenbein, 2001. How long after drug ingestion is activated charcoal still effective. J. Toxicol. Clin. Toxicol., 39: 601-605.
21. Gruchalla, R.S., 2000. Clinical assessment of drug-induced disease. Lancet, 356: 1505-1511.
22. Gunawan, B. and N. Kaplowitz, 2004. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev., 36: 301-312.
23. Hashkes, P. J., W.F. Balistren, K.E. Bove, E.T. Ballard and M.H. Passo, 1999. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J. Pediatr., 134: 47-52.
24. Hoofnagle, J.H., 2004. Drug-induced liver injury network (DILIN). Hepatology, 40: 773-773.
25. Ibanez, L., E. Perez, X. Vidal and J.R. Laporte, 2002. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: Epidemiological and clinical features and exposure to drugs. J. Hepatol., 37: 592-600.
26. Javed, A., A.M. Khan and M.B. Anwar, 2009. Liver toxicity caused by synthetic drugs. J. Chem. Pharm. Sci., 2: 265-269.
27. Katsinelos, P., T. Vasiliadis and P. Xiarchos, 2000. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin) induced intra-hepatic cholestasis: Report of two cases. Eur. J. Gastroenterol. Hepatol., 12: 365-368.
28. Kremer, J.M., D.E. Furst, M.E. Weinblatt and S.D. Blotner, 1996. Significant changes in serum AST across hepatic histological biopsy grades: Prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J. Rheumatol., 23: 459-461.
29. Kucers, A., N. Bennett and R.J. Kemp, 1987. The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. 4th Edn., Williams and Wilkins, Philadelphia, Lippincott, p: 20.
30. Larrey, D., 2002. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Seminars Liver Dis., 22: 145-155.
31. Lee, W.M. and W.T. Denton, 1989. Chronic hepatitis and indolent cirrhosis due to methyldopa: the bottom of the iceberg. J. South Carolina Med. Assoc, 85: 75-79.
32. Lewis, J.H., 1997. Monitoring for methotrexate hepatotoxicity in patients with rheumatoid arthritis: another hepatologists perspective. J. Rheumatol., 24: 1459-1460.
33. Lewis, J.H. and H.J. Zimmerman, 1998. Drug Induced Autoimmune Liver Disease. In: Autoimmune Liver Disease, Krawitt, E.L., R.H. Wiesner and M. Nishioka (Eds.). 2nd Edn., Elsevier, Amsterdam, pp: 627-649.
34. Lewis, J.H. and H.J. Zimmerman, 1999. Drug and chemical induced cholestasis. Clin. Liver Dis, 3: 433-464.
35. Lin, J.H. and G. Levy, 1981. Sulfate depletion after acetaminophen administration and replenishment by infusion of sodium sulfate or N-acetylcysteine in rats. Biochem. Pharmacol., 30: 2723-2725.
36. Lucena, M.I. R.J. Andrade, M.C. Fernandez, K. Pachkoria and G. Pelaez et al., 2006. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. Hepatology, 44: 850-856.
37. McBride, P.V. and B.H. Rumack, 1992. Acetaminophen intoxication. Seminar Dialysis, 5: 292-297.
38. Medical Economics, 2000. Physicians Desk Reference 2000. 54th Edn., Thomson PDR Publication, Montvale, NJ.
39. Morelli, S., V. Guido and P. De Marzio, 1991. Early hepatitis during intravenous amiodarone administration. Cardiology, 78: 291-294.
40. Mork, H., O. Al-Taie, O. Klinge and M. Scheurlen, 1997. Successful therapy of persistent androgen-induced cholestasis with ursodeoxycholic acid. Z. Gastroenterol, 35: 1087-1091.
41. Nelson, S.D., 1990. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Seminars Liver Dis., 10: 267-278.
42. Nilesh, M., L. Ozick and E. Gbadehan, 2009. Drug-induced hepatotoxicity: eMedicine critical care.http://emedicine.medscape.com/article/169814-overview.
43. Nolan, CM. S.V. Goldberg and S.E. Buskin, 1999. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic. JAMA, 281: 1014-1018.
44. O'Brien, C.B., D.S. Shields, S.H. Saul and R. Reddy, 1996. Drug induced vanishing bile duct syndrome: Response to ursodiol. Am. J. Gastroenterol., 91: 1456-1457.
45. Park, B.K., M. Pirmohamed and N.R. Kittrnngham, 1998. Role of drug disposition in drug hypersensitivity: A chemical, molecular and clinical perspective. Chem. Res. Toxicol., 11: 969-988.
46. Pineiro-Carrero, V.M. and E.O. Pineiro, 2004. Liver. Pediatrics, 113: 1097-1106.
47. Poison, J. and W.M. Lee, 2005. AASLD position paper: The management of acute liver failure. Hepatology, 41: 1179-1197.
48. Ramachandran, R. and S. Kakar, 2009. Histological patterns in drug-induced liver disease. J. Clin. Pathol., 62: 481-492.
49. Rawlins, M.D. and J.W. Thompson, 1977. Pathogenesis of Adverse Drug Reactions. In: Textbook of Adverse Drug Reactions, Davies, D.M. (Ed.). Oxford University Press, Oxford, pp: 10.
50. Singh, C, P. Bishop and R. Wilson, 1996. Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements and ethanol: Response to ursodeoxycholic acid treatment. Am. J. Gastroenterol, 91: 783-785.
51. Slattery, J.T., T.I. McRone, R. Reynolds, T.F. Kalhorn, E.D. Kharasch and A.C. Eddy, 1989. Lack of effect of Cimetidine on APAP disposition in humans. Clin. Pharm., 46: 591-597.
52. Smilkstein, M.J., A.C. Bronstein and C. Linden, 1991. Acetaminophen overdose: A 48-hour intravenous nacetylcysteine treatment protocol. Ann. Emerg. Med., 20: 1058-1063.
53. Squires, Jr. R.H., B.L. Shneider and J. Bucuvalas, 2006. Acute liver failure in children: The first 348 patients in the pediatric acute liver failure study group. J. Pediatr., 148: 652-658.
54. Sun, L., C. Luo, J. Long, D. Wei and J. Liu, 2006. Acrolein is a mitochondrial toxin: Effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Mitochondrion, 6: 136-142.
55. Tahaoglu, K., G. Atac and A.T. Sevim, 2001. The management of anti-tuberculosis drug-induced hepatotoxicity. Int. J. Tuberculosis Lung Dis., 5: 65-69.
56. Tan, H.H., C.Y. Chang and P. Martin, 2009. Acetaminophen hepatotoxicity: Current management. Mount Sinai J. Med., 76: 75-83.
57. Temple, R., 2002. Policy developments in regulatory approval. Stat. Med., 21: 2939-2948.
58. Trease, G.E. and W.C. Evans, 2002. Pharmacological Activities: Pharmacognosy. 15th Edn., Saunders Publishers, London, pp: 42-44.
59. Underbill, T.J., M.K. Greene and A. Dove, 1990. A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Arch. Emerg. Med., 7: 148-154.
60. Walgren, J.L., M.D. Mitchell and D.C. Thompson, 2005. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol, 35: 325-361.
61. Zimmerman, H.J., 1981. Effects of aspirin and acetaminophen on the liver. Arch. Internal Med., 141: 333-342.